SureTrader SureTrader
Home > Boards > US OTC > Medical - Healthcare >

Theralase Technologies Inc. (TLTFF)

Add TLTFF Price Alert      Hide Sticky   Hide Intro
Search This Board:
Last Post: 10/21/2016 11:47:12 AM - Followers: 48 - Board type: Free - Posts Today: 12


Jan 22, 2014 7:20 AM | about stocks: TLTFF


Theralase Technologies Inc. (TSX-V: TLT, US-OTCBB: TLTFF). They design, develop, manufacture and market, patented, super-pulsed laser technology used in biostimulative and biodestructive clinical applications. The Theralase technology platform targets several health-care sectors: First, for non-invasive pain management and clinical therapy, used in neural muscular skeletal conditions, including arthritis and osteoarthritis; Second, wound care and healing (including non-healing fractures and bone fracture regeneration); And third, research and development into combining patented photodynamic compounds (PDCs) with patented, super-pulsed, biofeedback laser technology to attack specifically targeted cancers, bacteria and viruses.

The company is currently focused on the commercialization (production, marketing and distribution) of the TLC-2000 Superpulsed Laser Technology to healthcare practitioners, and commercialization of the patented TLC-3000 Photo Dynamic Compound Cancer Technology through pre-clinical research and clinical trials.

Key Investment Highlights:

  • Working on breakthrough bladder cancer destruction technology and has achieved tremendous success in pre-clinical trials
    Proven clinical technology (TLC-1000) and commercial therapeutic laser business and brand developed over last 17 years, currently generating ~2M of revenue annually
    Rollout of new TLC-2000 technology in 2014, along with a new recurring revenue business model
    Strategic agreements in place with world renowned institutions to help advance research and mitigate expenses
    Competitive technical advantages (Cellular pathways: iNOS, ATP, Na+ / K+)
    Future technology (patented biofeedback technology and patented PDC cancer destruction)
    IP protection (multiple issued patents)
    Large addressable US markets ($ billions)
    No debt
    Positive cash flow / double digit growth
    Lots of opportunity for short-term and long-term growth (revenue & profit)
    Experienced management team (20+ years)
    Clear vision and execution strategy


Theralase has patented anti-cancer drugs known as Photo Dynamic Compounds (PDCs) which localize the DNA of cancer cells and when irradiated, destroy the DNA resulting in apoptosis (natural cell death). While PDCs are used in Photodynamic Therapy (PDT) as a potential treatment regime for a number of conditions, Theralase has discovered that they hold particular promise as treatment to particular cancers. Theralase PDCs have proven successful in destroying breast, colon, brain and bladder cancer cells. Recent lab results have shown that Theralase was able to completely destroy subcutaneous bladder cancer tumors in mouse models. "The achievement of this important milestone signifies that Theralase's leading drug candidate is effective in the destruction of cancer in a live animal model and can prevent the cancer from recurring," commented Roger White of Theralase.

Key Market Statistics:

  • US bladder cancer treatment annual spending was $3.9 billion in 2012
    70,000 new cases, > 14,000 deaths in the US each year
    386,000 new cases are diagnosed worldwide annually
    Standard treatment unchanged with no new drugs approved since 1998
    5th most common cancer, 4th in men, 8th in women
    Most expensive cancer to treat with a recurrence rate up to 80%
    70% of new bladder cancer cases are early stage disease and 90% of bladder cancers are Transitional Cell Carcinoma (TCC)

Theralase PDC Characteristics:

  • Up to 100% cancer cell kill at very low concentrations (< 0.8μM)

(click to enlarge)

  • More effective at killing cancer cells than FDA approved drugs

(668,000x ALA, 198x PHOTOFRIN)

  • Survival of mice up to 20 months (50 human years) after one Theralase PDT treatment

(click to enlarge)

We are VERY IMPRESSED, and VERY EXCITED about these results! In 2012, annual spending for bladder cancer treatment in the US was $3.9 billion, and the current standard of care has been unchanged with no new drugs approved since 1998. Bladder cancer is the most expensive cancer to treat, and has a recurrence rate up to 80%. All of the mice which showed an initial response have remained cancer free, healed without scarring, and have developed normally after only one Theralase PDC treatment. Needless to say, the early results from Theralase look extremely positive. Imagine being able to not only provide treatment for bladder cancer, but to actually cure it, and stop it from coming back! The company is also working on developing further PDCs that can be used to treat a wide variety of other cancers (breast, colon, brain and lung), as well as bacteria and viruses.

  • The general patent protects 1,000s of molecules - essentially a library of PDCs
    Virtually 0% toxicity at high concentrations (> 100μM) leading to ultra-high safety profile
    Activated by laser light providing excellent specificity and selectivity
    Able to treat solid core hypoxic tumors, such as: breast, prostate and lung
    Research outsourced to and performed at world renowned Princess Margaret Cancer Centre
    Patented under numerous US and International Patents:
    Issued USA Patents: 6,962,910, 7,612,057, 8,148,360, 8,445,475
    Pending USA Patent Applications: 61/801,674, 13/863,089, 13/36595

To help explain how the procedure works we sketched a diagram:

(click to enlarge)

  1. A catheter is inserted into the patient
    The PDC is injected and saturates within the patient's bladder, penetrating the cellular membrane (DNA localizing)
    Fiber optics cables are inserted up the catheter into the bladder
    Using laser technology, light is irradiated 360°
    The entire procedure takes about 2 - 3 hours

Theralase is currently completing the validation of the orthotopic rat model, a dose toxicity study, GMP drug manufacture, and FDA Investigational New Drug (IND) application. The next phase is to complete an FDA phase 1/2a human clinical study with FDA breakthrough status, and then to execute a strategic partnership agreement with big pharmaceutical (pharma) company (upfront payments, co-development funds, annual recurring revenue streams).

Industry comparables:

(click to enlarge)

(click to enlarge)

Deals with comparable big pharma companies have yielded anywhere from $466M to $1B plus royalties.


The thing is, by the time clinical trials have been completed (assuming they're successful), Theralase will be trading many multiples higher than today. Look how excited investors got when Theralase first released PDC breast cancer results during January 2010, the intraday high for TLT was $1.39/share:

Read More :

Themes: Biotechnology, Micro Capitalization, Growth Opportunity, Pharmaceuticals, Cancer, Laser Technology, Photo Dynamic Compounds (PDCs) Stocks: TLTFF
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
TLTFF News: Theralase Anti-Cancer Technology Picks Up Steam 01/06/2015 07:00:00 AM
TLTFF News: Theralase CEO to Be Interviewed Today on Clear Channel Business Talk Radio DFW 1190AM 03/12/2014 07:05:00 AM
TLTFF News: Theralase Achieves Commercialization Milestone For Its Bladder Cancer Therapy 03/14/2013 07:00:04 AM
#2135   I think Wall Street is waiting for proven 123414 10/21/16 11:47:12 AM
#2134   123414 10/21/16 11:45:41 AM
#2133   I think Wall Street is waiting for proven 123414 10/21/16 11:45:40 AM
#2132   Why isn't Wall Street reacting? Adrock 10/21/16 11:01:53 AM
#2131   This was the next BIG milestone. BIGKAHUNA57 10/21/16 10:03:01 AM
#2130   I see what you mean on Pricing. Opening IBjim 10/21/16 09:40:01 AM
#2129   It would be scandalous to bring this to 123414 10/21/16 09:19:24 AM
#2128   the miracle here is all the science from heavymetal 10/21/16 06:36:42 AM
#2127   I think there are more positives to this CUIN2 10/21/16 06:17:52 AM
#2126   I agree. The speed of the approval is 123414 10/21/16 05:49:07 AM
#2125   That could be a possibility. 123414 10/21/16 05:44:03 AM
#2124   I think they got caught by suprise with itsallgood11 10/21/16 12:56:39 AM
#2123   I am wondering if there is lag time CUIN2 10/20/16 09:22:57 PM
#2122   Today TLTFF + 11.69%. Some of the ITA 123414 10/20/16 04:42:46 PM
#2121   Lab/test/results = Unoffical fastrack. 123414 10/20/16 04:28:36 PM
#2120   My question is: how was HC able CUIN2 10/20/16 04:12:51 PM
#2119   I think administrators understand the incredible benefit this 123414 10/20/16 04:10:22 PM
#2118   At the end of the day, we are suerte88 10/20/16 02:16:59 PM
#2117   Won't work for long CUIN2 10/20/16 11:15:34 AM
#2116   When you see the ASK below the average BIGKAHUNA57 10/20/16 11:11:38 AM
#2115   Good volume. CUIN2 10/20/16 11:10:23 AM
#2114   if big pharma steps into the room, a heavymetal 10/20/16 11:08:24 AM
#2113   We have warrants for financing if pps goes BIGKAHUNA57 10/20/16 10:59:26 AM
#2112   So exited . Lets get that cancer beat. ! itsallgood11 10/20/16 10:25:26 AM
#2111   Agree. CUIN2 10/20/16 10:20:30 AM
#2110   Congratulations Theralase, et al. BIGKAHUNA57 10/20/16 10:19:06 AM
#2109   " demonstrating to the world what this technology heavymetal 10/20/16 09:36:54 AM
#2108   First trades at 9:30 am already up 17%. CUIN2 10/20/16 09:31:55 AM
#2107   Health Canada Grants Theralase ITA Approval Accesswire October 20, 2016 TORONTO CUIN2 10/20/16 09:28:10 AM
#2106   Theralase Technologies (TLT.V) – Interim Update Zacks Small Cap CUIN2 10/20/16 09:27:34 AM
#2105   Agree CUIN2 10/20/16 09:23:54 AM
#2104   every stockholder should be congratulated for their persistence heavymetal 10/20/16 09:22:28 AM
#2103   Glad you didn't? It was a surprise CUIN2 10/20/16 09:20:47 AM
#2102   And i almost sold some yesterday out of itsallgood11 10/20/16 09:15:12 AM
#2101   Yes it is. We could be on the verge CUIN2 10/20/16 09:08:05 AM
#2100   exciting to own this stock. heavymetal 10/20/16 09:04:54 AM
#2099   Glad I p/u 30k more shares at .273 yesterday. robwilly 10/20/16 08:27:38 AM
#2098   No More Waiting!! This approval confers great robwilly 10/20/16 08:08:06 AM
#2097   Not really sure. I would think some CUIN2 10/20/16 07:53:10 AM
#2096   Let's see how the market reacts suerte88 10/20/16 07:46:34 AM
#2095   Finally. CUIN2 10/20/16 07:41:03 AM
#2094   Da ist das Ding suerte88 10/20/16 07:34:47 AM
#2093   TORONTO, ON / ACCESSWIRE / October 20, 2016 CUIN2 10/20/16 07:09:38 AM
#2092   Site of interest . -3 10/19/16 08:03:53 AM
#2091   Excellent Product Potential 123414 10/18/16 11:55:56 AM
#2090   Ok, i agree suerte88 10/16/16 09:52:12 AM
#2089   I am sure they will do more tests MasterSalix 10/16/16 08:47:21 AM
#2088   CUIN thanks for the information. suerte88 10/16/16 05:40:40 AM
#2087   Great find. Appreciate that. BIGKAHUNA57 10/15/16 06:51:58 PM
#2086   Theralase expects bladder cancer trial green light by CUIN2 10/15/16 05:39:16 PM